LFM-A13
CAS No. : 62004-35-7
| Size | Price | Stock |
|---|---|---|
| 5mg | $95 | In-stock |
| 10mg | $155 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-110002 |
| M.Wt: | 360.00 |
| Formula: | C11H8Br2N2O2 |
| Purity: | >98 % |
| Solubility: | 10 mM in DMSO |
LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]
IC50 & Target:IC50: 2.5 μM (BTK)[1], 10 μM (Plx1), 61 μM (PLK3)[3]
In Vitro: LFM-A13 (100 μM; 4 h) inhibits Epo-induced phosphorylation of EpoR, JAK2, BTK, STAT5, and ERK1/2 in R10 cells[2].
LFM-A13 (100 μM; transfection 48 h) inhibits the autophosphorylation of JAK2, Tec and BTK in COS cells without affecting the autophosphorylation of Lyn kinase[2].
LFM-A13 potently inhibits Plx1 with IC50 of 10 μM; also inhibits BRK, BMX, FYN and Met with IC50s of 267, 281, 240 and 215 μM, respectively[3].
In Vivo: LFM-A13 (10 or 50 mg/kg; i.p.) exhibits anti-tumor effects dose dependently in the MMTV/Neu transgenic mouse model of breast cancer[3].
FM-A13 (50 mg/kg; tiw; i.p.) attenuates DMBA-induced mammary tumorigenesis in mice by modulating a variety of factors associated with cell cycle, survival and apoptosis[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- LFM-A13
- Cat. No.:
- HY-110002
- Quantity:
Your information is safe with us.